Clinical pharmacists integrated into multiple sclerosis care models and working alongside other providers can streamline the health care delivery process by optimizing and accelerating access to medications requiring prior authorization, can improve patient outcomes by promoting medication adherence and persistence, can enhance safety by monitoring laboratory findings and potential drug-drug interactions, and can minimize clinical workflow burden by improving process efficiency.
Nearly 25% of people with multiple sclerosis in our study reported wearing off prior to their next ocrelizumab infusion while on the standard 6-month dosing interval.
There are numerous instruments used to measure stigma in people with MS, creating ambiguity about different stigma types and their definitions and complicating the ability to generalize study findings.